Overall rank by patents
#24,301
Across all tracked assignees
USPTO PatentsView assignee record - 11 granted patents across 4 technology areas, active 2015–2022. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS).
The verdict
Estetra holds 11 US patents across 4 technology areas, rank #24,301 of 50,000 tracked assignees.
Estetra SPRL has been granted 11 US utility patents between 2015 and 2022, placing Estetra SPRL at rank #24,301 across all assignees tracked by PlainPatent. This portfolio spans 4 distinct Cooperative Patent Classification (CPC) subclasses, averaging 14.7 claims per patent with primary concentration in A61P (SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS). As a Foreign Corporation, Estetra SPRL is one of the more focused assignees in the PatentsView dataset. By volume, Estetra sits between Erowa Ag (11 patents, rank #24,297) and Evolv Technologies, Inc. (11 patents, rank #24,305) - the closest US assignees by grant volume. The composite Innovation Score of 26.4/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 9 grants, compared with 2 in the 2015–2019 window, a +350% shift in five-year velocity. An acceleration of this magnitude signals aggressive R&D investment and expanding technical ambition. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Estetra SPRL's 14.7 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while specialization in 4 subclasses reflects a tightly scoped invention area. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Estetra SPRL against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
Erowa AG
11 patents
Erwin Junker Maschinenfabrik GmbH
11 patents
Esdec B.V.
11 patents
Eseye Limited
11 patents
Eutropics Pharmaceuticals, Inc.
11 patents
EverPro Technologies Company Limited
11 patents
Everbridge, Inc.
11 patents
Evolv Technologies, Inc.
11 patents
Estetra SPRL
11 patents
What this shows Estetra holds 11 patents at rank #24,301, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Estetra's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
26 Top 80% higher than 20% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2015 | 1 | 9.1% |
| 2017 | 1 | 9.1% |
| 2020 | 2 | 18.2% |
| 2021 | 5 | 45.5% |
| 2022 | 2 | 18.2% |
Top 4 of 4 technology areas
Overall rank by patents
#24,301
Across all tracked assignees
26.4 out of 100
How to use this portfolio
Estetra's 11 grants land it in the top 80% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.